HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caleffi, M. Articles by Lewis, B. Search for Related Content PubMed PubMed Citation Articles by Caleffi, M. Articles by Lewis, B.

As part of a controlled trial of the use of tamoxifen for the treatment of mastalgia, some of the metabolic and haematological effects of this agent were measured. A panel of haemostatic variables including prothrombin time, kaolin cephalin clotting time, fibrinogen, euglobulin lysis time, factor VII, factor VIII, protein C and anti-thrombin III were determined. In addition, levels of sex hormone-binding globulin and both total and free oestradiol were estimated. No alteration in clotting function was found during the administration of tamoxifen, although hepatic function did alter during this period with an increase in concentration of sex hormone-binding globulin. There was a significant increase in total oestradiol and free oestradiol although the percentage of biologically available free oestradiol fell slightly during the course of tamoxifen treatment. There was a slight reduction in low-density lipoprotein cholesterol with an increase in HDL₂, a subclass of high-density lipoprotein (HDL) cholesterol, consistent with an oestrogen-agonist effect. These data suggest that tamoxifen administration does not adversely influence haemostatic mechanisms or lipoprotein metabolism in the short term.

J. Endocr. (1988) 119, 335–339

This article has been cited by other articles:

				A.R. Carmichael Can Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence? Evid. Based Complement. Altern. Med., September 1, 2008; 5(3): 247 - 250. [Abstract] [Full Text] [PDF]

				Y. Suarez, C. Fernandez, D. Gomez-Coronado, A. J. Ferruelo, A. Davalos, J. Martinez-Botas, and M. A. Lasuncion Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin Cardiovasc Res, November 1, 2004; 64(2): 346 - 355. [Abstract] [Full Text] [PDF]

				R. L. Smith, S. Pruthi, and L. A. Fitzpatrick Evaluation and Management of Breast Pain Mayo Clin. Proc., March 1, 2004; 79(3): 353 - 372. [Abstract] [PDF]

				C. J. Dearing and S. F. Harrison Tamoxifen-Induced Hypertriglyceridemia Journal of Pharmacy Practice, April 1, 1997; 10(2): 73 - 74. [PDF]

				J. Reckless, J. C. Metcalfe, and D. J. Grainger Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice Circulation, March 18, 1997; 95(6): 1542 - 1548. [Abstract] [Full Text]